Cost-effectiveness of letrozole versus tamoxifen as initial adjuvant therapy in postmenopausal women with hormone-receptor positive early breast cancer from a Canadian perspective
- 26 July 2007
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 108 (3) , 375-387
- https://doi.org/10.1007/s10549-007-9607-7
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98Journal of Clinical Oncology, 2007
- Cost-Effectiveness of Letrozole in the Extended Adjuvant Treatment of Women with Early Breast CancerBreast Cancer Research and Treatment, 2006
- Anastrozole is cost-effective vs tamoxifen as initial adjuvant therapy in early breast cancer: Canadian perspectives on the ATAC completed-treatment analysisSupportive Care in Cancer, 2006
- Cost Effectiveness of Extended Adjuvant Letrozole in Postmenopausal Women after Adjuvant Tamoxifen TherapyPharmacoEconomics, 2006
- A Comparison of Letrozole and Tamoxifen in Postmenopausal Women with Early Breast CancerNew England Journal of Medicine, 2005
- Use of Cost-Effectiveness Analysis in Health-Care Resource Allocation Decision-Making: How Are Cost-Effectiveness Thresholds Expected to Emerge?Value in Health, 2004
- Trends in Heart Failure Incidence and Survival in a Community-Based PopulationJAMA, 2004
- Willingness to Pay for a Quality-adjusted Life YearMedical Decision Making, 2000
- The Beaver Dam Health Outcomes studyMedical Decision Making, 1993
- Probabilistic Sensitivity Analysis Using Monte Carlo SimulationMedical Decision Making, 1985